Mark S. Yerby, MD, MPH

Mark S. Yerby, MD, MPH
North Pacific Epilepsy Research and Oregon Health and Science University, Portland, OR

Peter Kaplan, MB, FRCP
Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD

Teresa Tran, MD
MINCEP Epilepsy Care, Minneapolis, MN

Correspondence: Mark S. Yerby, MD, MPH, North Pacific Epilepsy Research, 2455 NW Marshall Street, Suite 14, Portland, OR 97210; e-mail: Yerby@seizures.net

Dr. Yerby is an unpaid consultant for GlaxoSmithKline and is on the speakers' bureau for Elan, GlaxoSmithKline, Abbott, and Xcel Pharmaceuticals.

Dr. Kaplan receives grants/research support from GlaxoSmithKline, Pfizer/Parke-Davis, UCB Pharma, and Marion Merrill Dow; is a consultant for Abbott, GlaxoSmithKline, Pfizer/Parke-Davis, Novartis, UCB Pharma, Elan, and Ortho-McNeil; and is on the speakers' bureau for Abbott, GlaxoSmithKline, Pfizer/Parke-Davis, Novartis, and UCB Pharma. Dr. Kaplan notes that he is not a major stock shareholder in any of the above companies.

Dr. Tran has indicated she has nothing to disclose.

Mark S. Yerby, MD, MPH
North Pacific Epilepsy Research and Oregon Health and Science University, Portland, OR

Peter Kaplan, MB, FRCP
Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD

Teresa Tran, MD
MINCEP Epilepsy Care, Minneapolis, MN

Correspondence: Mark S. Yerby, MD, MPH, North Pacific Epilepsy Research, 2455 NW Marshall Street, Suite 14, Portland, OR 97210; e-mail: Yerby@seizures.net

Dr. Yerby is an unpaid consultant for GlaxoSmithKline and is on the speakers' bureau for Elan, GlaxoSmithKline, Abbott, and Xcel Pharmaceuticals.

Dr. Kaplan receives grants/research support from GlaxoSmithKline, Pfizer/Parke-Davis, UCB Pharma, and Marion Merrill Dow; is a consultant for Abbott, GlaxoSmithKline, Pfizer/Parke-Davis, Novartis, UCB Pharma, Elan, and Ortho-McNeil; and is on the speakers' bureau for Abbott, GlaxoSmithKline, Pfizer/Parke-Davis, Novartis, and UCB Pharma. Dr. Kaplan notes that he is not a major stock shareholder in any of the above companies.

Dr. Tran has indicated she has nothing to disclose.

Mark S. Yerby, MD, MPH
North Pacific Epilepsy Research and Oregon Health and Science University, Portland, OR

Peter Kaplan, MB, FRCP
Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, MD

Teresa Tran, MD
MINCEP Epilepsy Care, Minneapolis, MN

Correspondence: Mark S. Yerby, MD, MPH, North Pacific Epilepsy Research, 2455 NW Marshall Street, Suite 14, Portland, OR 97210; e-mail: Yerby@seizures.net

Dr. Yerby is an unpaid consultant for GlaxoSmithKline and is on the speakers' bureau for Elan, GlaxoSmithKline, Abbott, and Xcel Pharmaceuticals.

Dr. Kaplan receives grants/research support from GlaxoSmithKline, Pfizer/Parke-Davis, UCB Pharma, and Marion Merrill Dow; is a consultant for Abbott, GlaxoSmithKline, Pfizer/Parke-Davis, Novartis, UCB Pharma, Elan, and Ortho-McNeil; and is on the speakers' bureau for Abbott, GlaxoSmithKline, Pfizer/Parke-Davis, Novartis, and UCB Pharma. Dr. Kaplan notes that he is not a major stock shareholder in any of the above companies.

Dr. Tran has indicated she has nothing to disclose.